Health-care companies rose as traders rotated into sectors less susceptible to rising fuel prices and interest rates.
Wegovy maker Novo Nordisk plans to rebrand itself as Novo, betting a shorter name will help it resonate more with consumers as it competes with rival Eli Lilly.
AstraZeneca said its new breast-cancer pill missed the key goal of slowing the disease from worsening in a late-stage clinical trial. Shares of the British drug maker still gained.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.